PCSK9 is an enzyme accepted as a new biomarker for the lipid metabolism, a novel therapeutic target for hypercholesterolemia, because the inhibition of PCSK9 may be one of the options for lowering cardiovascular risk [47–49]. The gene discussed is PCSK9; the disease is familial hypercholesterolemia.